(Reuters) -Invitae Corp said on Monday a group of investors including SoftBank Group Corp will invest $1.15 billion in the U.S. genetic diagnostics company.
It said the investment, to be used for its growth initiatives, will be in convertible senior notes, which will bear 1.5% interest per year.
The company said the notes will have an initial conversion price of $43.18 per share of its common stock, representing a premium of 10.2% to Invitae’s closing price on Friday.
Earlier this year, SoftBank invested $900 million in gene sequencing firm Pacific Biosciences of California Inc.
San Francisco-based Invitae offers genetic testing services for a range of diseases, including skin and eye conditions, cancers as well as reproductive health in and outside the United States.
Shares of the company, which started operations in 2010, have more than tripled in the past twelve months, giving it a market valuation of $7.7 billion.
J. Wood Capital Advisors LLC and Perella Weinberg Partners LP were financial advisers to Invitae on the transaction.
Reporting by Amruta Khandekar in Bengaluru; Editing by Shinjini Ganguli
Our Standards: The Thomson Reuters Trust Principles.
The pending deal would connect asset-backed financing with its tokenization business, but market-size figures do…
The automotive-parts supplier ends its interim leadership arrangement more than a month ahead of the…
A joint ministerial statement calls for sectoral discussions and an end to market-distorting policies, without…
Wärtsilä’s 35-megawatt storage project pairs batteries with energy management and maintenance, with takeover expected in…
The federal contractor reports customer expansion and retained work, but contract ceilings and unexercised options…
Stamford is set to become the American base for one of Europe’s most ambitious fintech…